版本:
中国

BRIEF-Ligand says initiates phase 2 trial with LGD-6972

Sept 13 Ligand Pharmaceuticals Inc :

* Initiates Phase 2 trial with LGD-6972 in type 2 diabetes

* Says multiple site study is expected to enroll 148 subjects with T2DM

* Says estimates study will be completed in late 2017 Source text for Eikon: Further company coverage:

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐